MiR-376a and histone deacetylation 9 form a regulatory circuitry in hepatocellular carcinoma

Cellular Physiology and Biochemistry

Volumn 35, Issue 2, 2015, Pages 729-739

  Zheng, Yongxia ^a   Chen, Huan ^b   Yin, Manxiang ^c   Ye, Xiaoqian ^c   Chen, Guiqian ^a   Zhou, Xinmei ^a   Yin, Lei ^d   Zhang, Chengwen ^a   Ding, Baoyue ^a  

^a JIAXING UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c Hospital of Zhejiang General Corps of Armed Police Forces   (China)

^d SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

HDAC9; Hepatocellular Carcinoma; MiR 376a

Indexed keywords

HISTONE DEACETYLASE 9; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; LYSINE 18 OF HISTONE 3; MATERNALLY EXPRESSED 3; MICRORNA; MICRORNA 376A; PROTEIN; UNCLASSIFIED DRUG; AZACITIDINE; DECITABINE; HDAC9 PROTEIN, HUMAN; HISTONE DEACETYLASE; MIRN376 MICRORNA, HUMAN; REPRESSOR PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEACETYLATION; DNA MODIFICATION; DOWN REGULATION; ENZYME ACTIVITY; GENE EXPRESSION; HISTONE ACETYLATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; PRIORITY JOURNAL; UPREGULATION; ANALOGS AND DERIVATIVES; DRUG EFFECTS; GENETIC EPIGENESIS; GENETICS; LIVER TUMOR; METABOLISM; MUTATION; PATHOLOGY; TUMOR CELL LINE;

AZACITIDINE; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; DOWN-REGULATION; EPIGENESIS, GENETIC; HISTONE DEACETYLASES; HUMANS; LIVER NEOPLASMS; MICRORNAS; MUTATION; REPRESSOR PROTEINS;

EID: 84921841016     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000369733     Document Type: Article

References (30)

1. Forner A, Llovet JM, Bruix J: Hepatocellular carcinoma. Lancet 2012; 379: 1245-1255.
2. Pan H, Fu X, Huang W: Molecular mechanism of liver cancer. Anticancer Agents Med Chem 2011; 11: 493-499.
3. Zheng Y, Yin L, Chen H, Yang S, Pan C, Lu S, Miao M, Jiao B: miR-376a suppresses proliferation and induces apoptosis in hepatocellular carcinoma. FEBS Lett 2012; 586: 2396-2403.
4. Seitz H, Royo H, Bortolin ML, Lin SP, Ferquson-Smith AC, Cavaille J: A Large Imprinted microRNA Gene Cluster at the Mouse Dlk1-Gtl2 Domain. Genome Res 2004; 14: 1741-1748.
5. Stadtfeld M, Apostolou E, Akutsu H, Fukuda A, Follett P, Natesan S, Kono T, Shida T, Hochedlinger K: Aberrant silencing of imprinted genes on chromosome 12qF1 in mouse induced pluripotent stem cells. Nature 2010; 465: 175-181.
6. Mcmurray EN, Schmidt JV: Identification of imprinting regulators at the meg3 differentially methylated region. Genomics 2012; 100: 184-194.
7. Zhang L, Volinia S, Bonome T, Calin GA, Greshock J, Yang N, Liu CG, Ginnakakis A, Alexious P, Haseqawa K, Johnstone CN, Megraw MS, Adams S, Lassus H, Huang J, Kaur S, Liang S, Sethupathy P, Leminen A, Simossis VA, Sandaltzopoulos R, Naomoto Y, Katsaros D, Gimotty PA, Demichele A, Huang Q, Butzow R, Rustqi AK, Weber BL, Birrer MJ, Hatzigeorqiou AG, Corce CM, Coukos G: Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer. Proc Natl Acad Sci USA 2008; 105: 7004-7009.
8. Witt O, Deubzer HE, Milde T, Oehme I: HDAC family: What are the cancer relevant targets? Cancer Lett 2009; 277: 8-21.
9. Bai X, Wu L, Liang T, Liu Z, Li J, Li D, Xie H, Yin S, Yu J, Lin Q, Zheng S: Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 83-91.
10. Roccaro AM, Sacco A, Jia X, Azab AK, Maiso P, Ngo HT, Azab F, Runnels J, Quang P, Ghobrial IM: microRNA-dependent modulation of histone acetylation in Waldenstrom macroglobulinemia. Blood 2010; 116: 1506-1514.
11. Liu S, Wu LC, Pang J, Santhanam R, Schiwind S, Wu YZ, Hickey CJ, Becher H, Maharry K, Radmacher MD, Li C, Whitman SP, Mishra A, Stauffer N, Eiring AM, Briesewitz R, Baiocchi RA, Chan KK, Paschka P, Caligiuri MA, Byrd JC, Corce CM, Bloomfield CD, Perrotti D, Garzon R, Marcucci G: Sp1/NFkB/HADC/miR-29b regulatory network in KIT-driven myeloid leukemia. Cancer Cell 2010; 17: 333-347.
12. Yuan JH, Yang F, Chen BF, Lu Z, Huo XS, Zhou WP, Wang F, Sun SH: The Histone Deacetylase 4/Sp1/miR-200a Regulatory Network Contributes to Aberrant Histone Acetylation in Hepatocellular Carcinoma. Hepatology 2011; 54: 2025-2035.
13. Noonan EJ, Place RF, Pookot D, Basak S, Whitson JM, Hirata H, Giardina C, Dahiya R: miR-449a targets HDAC-1 and induces growth arrest in prostate cancer. Oncogene 2009; 28: 1714-1724.
14. Kumar R, Xi Y: microRNA, epigenetic machinery and lung cancer. Thoracic Cancer 2011; 2: 35-44.
15. Xu Y, Guo Y, Liu L, Cai R, Qian C: The Reciprocal Modulation Between Epigenetic and microRNA and The Application for Treatment of Malignant Tumors. Progress in Biochemistry and Biophysis 2008; 35: 1343-1350.
16. Liep J, Rabien A, Jung K: Feedback networks between microRNAs and epigenetic modifications in urological tumors. Epigenetics 2012; 7: 315-325.
17. Maruyama R, Suzuki H, Yamamoto E, Imai K, Shinomura Y: Emerging links between epigenetic alterations and dysregulation of noncoding RNAs in cancer. Tumor Biol 2012; 33: 277-285.
18. Yan K, Cao Q, Reilly CM, Young NL, Garcia BA, Mishra N: Histone deacetylase 9 deficiency protects against effector T cell-mediated systemic autoimmunity. J Biol Chem 2011; 286: 28833-28843.
19. Bertos NR, Wang AH, Yang XJ. Class II histone deacetylases: structure, function and regulation. Biochem Cell Biol 2001; 79: 243-252.
20. Lachenmayer A, Toffanin S, Cabellos L, Alsinet C, Hoshida Y, Villanueva A, Minquez B, Tsai HW, Ward SC, Thung S, Friedman SL, Lovet JM: Combination therapy for hepatocellu-lar carcinoma: additive preclinical efficacy of the HDAC inhibitor panobinostat with sorafenib. J Hepatol 2012; 56: 1343-1350.
21. Komatsu N, Kawamata N, Takeuchi S, Yin D, Chien W, Miller CW, Koeffler HP: SAHA, a HDAC inhibitor, has profound anti-growth activity against non-small cell lung cancer cells. Oncol Rep 2006; 15: 187-191.
22. Platta CS, Greenblatt DY, Kunnimalaiyaan M, Chen H: The HDAC inhibitor trichostatin A inhibits growth of small cell lung cancer cells. J Surg Res 2007; 142: 219-226.
23. Rikkishi H: Autophagic and apoptotic effects of HDAC inhibitors on cancer cells. J Biomed Biotechnol 2011; 830260.
24. Kaluza D, Kroll J, Gesierich S, Manavski Y, Boeckel JN, Doebele C, Zelent A, Rossiq L, Zeiher AM, Augustin HG, Urbich C, Dimmeler S: Histone deacetylase 9 promotes angiogenesis by targeting the antiangiogenic miRNA17-92 cluster in endothelial cells. Arterioscler Thromb Vasc Biol 2013; 33: 533-543.
25. Archer KJ, Mas VR, Maluf DG, Fisher RA: High-throught assessment of CpG site methylation for distinguishing between HCV-cirrhosis and HCV-associated hepatocellular carcinoma. Mol Genet Genomics 2010; 283: 341-349.
26. Bai X, Wu L, Liang T, Liu Z, Li J, Li D, Xie H, Yin S, Yu J, Lin Q, Zheng S: Overexpression of myocyte enhancer factor 2 and histone hyperacetylation in hepatocellular carcinoma. J Cancer Res Clin Oncol 2008; 134: 83-91.
27. Petrie K, Guidez F, Howell L, Healy L, Waxman S, Greaves M, Zelent A: The histone deacetylase 9 gene encodes multiple protein isoforms. J Biol Chem 2003; 278: 16059-16072.
28. Fiore R, Khudayberdiev S, Christensen M, Siegel G, Flavell SW, Kim TK, Greenberg ME, Schratt G: Mef2-mediated transcription of the miR379-410 cluster regulates activity-dependent dendritogenesis by fine-tuning Pumilio2 protein levels. EMBO J 2009; 28: 697-710.
29. Brandman O, Ferrell JE Jr, Li R, Meyer T: Interlinked fast and slow positive feedback loops drive reliable cell decisions. Science 2005; 310: 496-498.
30. Kobayashi T, Chen L, Aihara K: Modeling genetic swithes with positive feedback circuits. J Theor Biol 2003; 221: 379-399.